Hyppää sisältöön
    • Suomeksi
    • In English
  • Suomeksi
  • In English
  • Kirjaudu
Näytä aineisto 
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
JavaScript is disabled for your browser. Some features of this site may not work without it.

False-positive cardiac troponin I values due to macrotroponin in healthy athletes after COVID-19

Hammerer-Lercher, Angelika; Kissel, Christine K.; Wittfooth, Saara; Junes, Helea; Kaplan, Emel; Huré, Gabrielle; Sanzone, Alessandra; Neyer, Peter; Bernasconi, Luca; Manka, Robert; Noack, Patrik; Hof, Daniëlle; Hammarsten, Ola; Mueller, Christian

False-positive cardiac troponin I values due to macrotroponin in healthy athletes after COVID-19

Hammerer-Lercher, Angelika
Kissel, Christine K.
Wittfooth, Saara
Junes, Helea
Kaplan, Emel
Huré, Gabrielle
Sanzone, Alessandra
Neyer, Peter
Bernasconi, Luca
Manka, Robert
Noack, Patrik
Hof, Daniëlle
Hammarsten, Ola
Mueller, Christian
Katso/Avaa
10.1515_cclm-2025-0427.pdf (1.263Mb)
Lataukset: 

Walter de Gruyter GmbH
doi:10.1515/cclm-2025-0427
URI
https://doi.org/10.1515/cclm-2025-0427
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe202601217116
Tiivistelmä

Objectives

Cardiac troponins (cTn) are used to detect and quantify acute cardiomyocyte injury. In patients presenting with symptoms that could indicate myocarditis, elevated cTn concentrations typically mandate cardiac catheterization and heart muscle biopsy or cardiac magnetic resonance imaging (CMR). Accordingly, increased cTn levels due to macrotroponin – a complex between patient anti-troponin autoantibodies and cTn – could lead to unnecessary and potentially harmful interventions. In athletes, ensuring cardiac health after infection like COVID-19 is critical, but the occurrence of false-positive cTn levels post-COVID-19 remains unknown.

Methods

This observational study prospectively included 35 healthy athletes (aged 16–75 years; 19 females, 16 males) who underwent post-COVID check-ups during 2022–2023. Athletes’ cTn levels were measured using four different hs-cTn routine immunoassays. If discrepancies were noted between assays, further testing for macrotroponin was conducted using protein G column, sucrose gradient ultracentrifugation and anti-troponin autoantibody immunoassay.

Results

Seventeen athletes had normal cTn levels across all assays, while 18 (51 %) had elevated cTn, mostly cTnI. Despite elevated cTn levels, no signs of myocarditis or other cardiac conditions were found on electrocardiography, echocardiography, or CMR. Macrotroponin was confirmed among 16 of these 18 athletes. Further, IgG anti-troponin autoantibodies correlated significantly with the levels of the two most-commonly affected assays: hs-cTnI-Siemens Atellica and hs-cTnI-Abbott Alinity.

Conclusions

Post-COVID-19, nearly half of athletes showed elevated cTnI levels due to interference from macrotroponin. Awareness among physicians and laboratorians of this analytical confounder can avoid unnecessary invasive or costly diagnostic tests in athletes with false-positive cTnI levels after COVID-19.

Kokoelmat
  • Rinnakkaistallenteet [29337]

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste
 

 

Tämä kokoelma

JulkaisuajatTekijätNimekkeetAsiasanatTiedekuntaLaitosOppiaineYhteisöt ja kokoelmat

Omat tiedot

Kirjaudu sisäänRekisteröidy

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste